|
1
|
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
|
Cell
|
2010
|
3.37
|
|
2
|
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2008
|
2.80
|
|
3
|
Extranodal marginal zone lymphoma of the ocular adnexa.
|
Blood
|
2009
|
2.65
|
|
4
|
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.
|
Blood
|
2008
|
2.36
|
|
5
|
Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.
|
Am J Clin Pathol
|
2010
|
2.10
|
|
6
|
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
|
Br J Haematol
|
2009
|
2.09
|
|
7
|
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation.
|
Blood
|
2005
|
1.99
|
|
8
|
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.
|
Blood
|
2006
|
1.94
|
|
9
|
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
|
J Clin Oncol
|
2007
|
1.88
|
|
10
|
BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma.
|
Blood
|
2003
|
1.73
|
|
11
|
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.
|
Blood
|
2002
|
1.68
|
|
12
|
Primary bone lymphoma--the University of Miami experience.
|
Leuk Lymphoma
|
2010
|
1.68
|
|
13
|
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
|
Blood
|
2013
|
1.60
|
|
14
|
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
|
Blood
|
2008
|
1.55
|
|
15
|
Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases.
|
Leuk Lymphoma
|
2013
|
1.52
|
|
16
|
Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.
|
Leuk Lymphoma
|
2010
|
1.46
|
|
17
|
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
|
Leuk Lymphoma
|
2009
|
1.44
|
|
18
|
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.
|
Blood
|
2011
|
1.41
|
|
19
|
Association between non-Hodgkin lymphoma and renal cell carcinoma.
|
Leuk Lymphoma
|
2011
|
1.41
|
|
20
|
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.
|
Blood
|
2002
|
1.40
|
|
21
|
Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci.
|
Blood
|
2005
|
1.38
|
|
22
|
PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.
|
Blood
|
2008
|
1.32
|
|
23
|
Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
|
Blood
|
2004
|
1.25
|
|
24
|
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
|
Mol Cell Biol
|
2007
|
1.20
|
|
25
|
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.
|
Proc Natl Acad Sci U S A
|
2012
|
1.19
|
|
26
|
Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues.
|
Diagn Mol Pathol
|
2007
|
1.17
|
|
27
|
MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
|
Clin Cancer Res
|
2011
|
1.17
|
|
28
|
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.
|
Lab Invest
|
2007
|
1.16
|
|
29
|
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors.
|
EMBO J
|
2012
|
1.12
|
|
30
|
Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.
|
Blood
|
2006
|
1.09
|
|
31
|
HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration.
|
Blood
|
2007
|
1.08
|
|
32
|
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients.
|
Blood
|
2002
|
1.07
|
|
33
|
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.
|
Blood
|
2009
|
1.07
|
|
34
|
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.
|
Blood
|
2007
|
1.06
|
|
35
|
What is the institutional financial impact of an MD-PhD program without extramural funding?
|
Teach Learn Med
|
2010
|
1.03
|
|
36
|
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
|
Blood
|
2013
|
1.02
|
|
37
|
Primary diffuse large cell lymphoma of the mandible.
|
Leuk Lymphoma
|
2004
|
1.01
|
|
38
|
Central nervous system manifestations of marginal zone B-cell lymphoma.
|
Ann Hematol
|
2010
|
0.98
|
|
39
|
Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.
|
Nat Commun
|
2013
|
0.98
|
|
40
|
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
|
Proc Natl Acad Sci U S A
|
2010
|
0.98
|
|
41
|
HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway.
|
Blood
|
2010
|
0.97
|
|
42
|
Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors.
|
J Neurooncol
|
2010
|
0.97
|
|
43
|
miR-155 regulates HGAL expression and increases lymphoma cell motility.
|
Blood
|
2011
|
0.96
|
|
44
|
Darinaparsin: a novel organic arsenical with promising anticancer activity.
|
Expert Opin Investig Drugs
|
2009
|
0.96
|
|
45
|
A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
|
Proc Natl Acad Sci U S A
|
2011
|
0.96
|
|
46
|
Utility of positron emission tomography scans in mantle cell lymphoma.
|
Am J Hematol
|
2011
|
0.95
|
|
47
|
The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.
|
Am J Clin Pathol
|
2009
|
0.94
|
|
48
|
Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature.
|
Medicine (Baltimore)
|
2014
|
0.93
|
|
49
|
Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma.
|
Leuk Lymphoma
|
2009
|
0.93
|
|
50
|
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.
|
Mod Pathol
|
2012
|
0.93
|
|
51
|
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.
|
Mod Pathol
|
2010
|
0.92
|
|
52
|
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
|
J Clin Oncol
|
2013
|
0.91
|
|
53
|
Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database.
|
Leuk Lymphoma
|
2008
|
0.91
|
|
54
|
Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience.
|
Br J Haematol
|
2010
|
0.91
|
|
55
|
Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin.
|
FEBS J
|
2011
|
0.91
|
|
56
|
LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
|
Haematologica
|
2011
|
0.90
|
|
57
|
Ocular involvement as the initial manifestation of T-cell chronic lymphocytic leukemia.
|
Am J Ophthalmol
|
2007
|
0.90
|
|
58
|
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.
|
Blood
|
2012
|
0.90
|
|
59
|
Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components.
|
Am J Surg Pathol
|
2010
|
0.90
|
|
60
|
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
|
J Clin Invest
|
2013
|
0.89
|
|
61
|
Molecular outcome prediction in diffuse large-B-cell lymphoma.
|
N Engl J Med
|
2009
|
0.88
|
|
62
|
Biased use of the IGHV4 family and evidence for antigen selection in Chlamydophila psittaci-negative ocular adnexal extranodal marginal zone lymphomas.
|
PLoS One
|
2011
|
0.87
|
|
63
|
Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis.
|
Br J Haematol
|
2008
|
0.87
|
|
64
|
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
|
Br J Haematol
|
2014
|
0.86
|
|
65
|
Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.
|
Br J Haematol
|
2010
|
0.86
|
|
66
|
Ocular Adnexal Lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis.
|
Br J Haematol
|
2008
|
0.86
|
|
67
|
Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms.
|
Haematologica
|
2007
|
0.86
|
|
68
|
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.
|
Br J Haematol
|
2013
|
0.86
|
|
69
|
Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
|
Br J Haematol
|
2009
|
0.85
|
|
70
|
Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
|
Leuk Lymphoma
|
2002
|
0.85
|
|
71
|
Immunoarchitectural patterns in nodal marginal zone B-cell lymphoma: a study of 51 cases.
|
Am J Clin Pathol
|
2009
|
0.84
|
|
72
|
Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.
|
Int J Hematol
|
2012
|
0.84
|
|
73
|
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
|
Br J Haematol
|
2009
|
0.83
|
|
74
|
Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas.
|
Am J Hematol
|
2013
|
0.82
|
|
75
|
LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
|
Br J Haematol
|
2014
|
0.82
|
|
76
|
Pharmacotherapy of large B-cell lymphoma.
|
Expert Opin Pharmacother
|
2008
|
0.81
|
|
77
|
Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
|
Leuk Lymphoma
|
2007
|
0.81
|
|
78
|
Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis.
|
Leuk Lymphoma
|
2011
|
0.81
|
|
79
|
Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas.
|
Am J Pathol
|
2010
|
0.81
|
|
80
|
Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature.
|
Leuk Lymphoma
|
2005
|
0.81
|
|
81
|
Somatically mutated immunoglobulin IGHV@ genes without intraclonal heterogeneity indicate a postgerminal centre origin of primary intraocular diffuse large B-cell lymphomas.
|
Br J Haematol
|
2007
|
0.81
|
|
82
|
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
|
Br J Haematol
|
2013
|
0.80
|
|
83
|
Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma.
|
Am J Clin Pathol
|
2010
|
0.80
|
|
84
|
Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma.
|
Mod Pathol
|
2008
|
0.80
|
|
85
|
Biased immunoglobulin light chain use in the Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas.
|
Am J Hematol
|
2013
|
0.80
|
|
86
|
A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
|
Am J Hematol
|
2011
|
0.80
|
|
87
|
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.
|
Int J Mol Epidemiol Genet
|
2011
|
0.79
|
|
88
|
C-C chemokine receptor 1 expression in human hematolymphoid neoplasia.
|
Am J Clin Pathol
|
2010
|
0.78
|
|
89
|
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.
|
Br J Haematol
|
2014
|
0.78
|
|
90
|
The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow.
|
Am J Clin Pathol
|
2011
|
0.78
|
|
91
|
PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.
|
FEBS J
|
2011
|
0.77
|
|
92
|
The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma.
|
European J Clin Med Oncol
|
2010
|
0.77
|
|
93
|
Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma.
|
Leuk Lymphoma
|
2003
|
0.77
|
|
94
|
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
95
|
Expression of miRNAs in lymphocytes: a review.
|
Methods Mol Biol
|
2010
|
0.77
|
|
96
|
Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab.
|
Leuk Lymphoma
|
2004
|
0.77
|
|
97
|
Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.
|
Am J Clin Pathol
|
2011
|
0.76
|
|
98
|
HGAL protein expression persists in disorders of germinal center dissolution: potential role of HGAL in the germinal center microenvironment.
|
Appl Immunohistochem Mol Morphol
|
2011
|
0.76
|
|
99
|
Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
|
Int J Cancer
|
2014
|
0.76
|
|
100
|
Newly emerging therapies targeting viral-related lymphomas.
|
Curr Oncol Rep
|
2011
|
0.76
|
|
101
|
Molecular prognostic factors in diffuse large B-cell lymphoma.
|
Curr Treat Options Oncol
|
2005
|
0.75
|
|
102
|
Primary testicular lymphoma: the site matters.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
103
|
Lymphoma associated hemophagocytic syndrome: it's going viral.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
104
|
Rare PTCLs: treatment lagging behind pathobiologic advances.
|
Oncology (Williston Park)
|
2010
|
0.75
|
|
105
|
Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germinal center.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
106
|
Gene expression profiling in diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2007
|
0.75
|
|
107
|
Successful use of semi-nested PCR for the diagnosis of primary intraocular lymphoma.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
108
|
Chronic lymphocytic leukemia-associated nephrotic syndrome caused by focal segmental glomerulosclerosis.
|
Am J Hematol
|
2004
|
0.75
|
|
109
|
LMO2 protein expression predicts survival in patients with rheumatoid arthritis and diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
110
|
Hematodermic tumor presenting with generalized skin involvement.
|
J Clin Oncol
|
2009
|
0.75
|
|
111
|
LymphomiRs: microRNAs with regulatory roles in lymphomas.
|
Curr Opin Hematol
|
2015
|
0.75
|
|
112
|
Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.
|
Appl Immunohistochem Mol Morphol
|
2013
|
0.75
|